Discover
LBRX
LB Pharmaceuticals Inc
31.89
2 x 23.57
2 x 40.83
bid
ask
-
0.56
1.74%
2 @ 04:00 PM
31.89 +0.00 (0.00%)
| Ytd | 43.26% | |
| 1y | 84.34% |
31.60
day range
33.29
13.36
52 week range
33.47
| Open | 32.79 | Prev Close | 32.45 | Low | 31.60 | High | 33.29 | Mkt Cap | 914.50M |
| Vol | 220.94K | Avg Vol | 263.30K | EPS | -1.36 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-15 | 50-d Avg | 30.04 | 200-d Avg | 22.83 | 1yr Est | 0.00 |
| Income Statement | |||
| Operating Expenses | 22.10M | ||
| Research and Development Expense | 14.65M | ||
| Selling, General and Administrative Expense | 7.46M | ||
| Operating Income | -22.10M | ||
| Net Income | -19.05M | ||
| Net Income Common Stock | -19.05M | ||
| Net Income Common Stock (USD) | -19.05M | ||
| Consolidated Income | -19.05M | ||
| Earnings per Basic Share | -0.67 | ||
| Earnings per Basic Share (USD) | -0.67 | ||
| Earnings per Diluted Share | -0.67 | ||
| Earning Before Interest & Taxes (EBIT) | -19.05M | ||
| Earning Before Interest & Taxes (USD) | -19.05M | ||
| Weighted Average Shares | 28.24M | ||
| Weighted Average Shares Diluted | 28.24M | ||
| Balance Sheet | |||
| Cash and Equivalents | 321.45M | ||
| Cash and Equivalents (USD) | 321.45M | ||
| Investments | 44.96M | ||
| Investments Current | 44.96M | ||
| Current Assets | 389.07M | ||
| Property, Plant & Equipment Net | 3.63M | ||
| Total Assets | 393.48M | ||
| Debt Current | 730.00K | ||
| Total Debt | 3.47M | ||
| Current Liabilities | 10.91M | ||
| Debt Non-Current | 2.74M | ||
| Total Liabilities | 14.79M | ||
| Accumulated Retained Earnings (Deficit) | -148.58M | ||
| Accumulated Other Comprehensive Income | 208.00K | ||
| Shareholders Equity | 378.69M | ||
| Shareholders Equity (USD) | 378.69M | ||
| Assets Non-Current | 4.41M | ||
| Total Debt (USD) | 3.47M | ||
| Liabilities Non-Current | 3.88M | ||
| Trade and Non-Trade Payables | 7.12M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 132.00K | ||
| Net Cash Flow from Financing | 93.83M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 70.51M | ||
| Capital Expenditure | -32.00K | ||
| Issuance (Purchase) of Equity Shares | 93.83M | ||
| Net Cash Flow from Investing | -32.00K | ||
| Net Cash Flow from Operations | -23.29M | ||
| Share Based Compensation | 2.57M | ||